Manager TitleAgeSince
Chief Executive Officer 55 01/07/2022
Chief Executive Officer 77 31/03/1986
Director of Finance/CFO 70 22/01/2024
Director TitleAgeSince
Chairman 77 01/09/1989
Director/Board Member 55 01/07/2022
Chairman 60 01/05/2022
Date Insider Type Main position Quantity % Market Cap.
11/11/22Other

Chief Executive Officer

0 -
11/11/22Other

Chief Financial Officer

4,421,299 -
11/11/22Other

Chief Executive Officer

37,049,320 -
Change 5-day change 1-year change 3-year change Capi.($)
+9.72%+22.40% - - 18.29M
-0.68%+2.85%+18.72%-7.81% 66.11B
-1.97%-3.45%+50.62%+221.13% 55.3B
-1.13%+40.50%+40.50%+40.50% 42.44B
+0.23%+8.55%-49.77%-53.33% 41.28B
-3.54%-3.77%+56.89%-26.85% 30.78B
+2.56%+17.36%+168.28%-30.85% 32.46B
-1.06%+0.84%+68.91%+83.93% 23.1B
-3.54%+9.67%+5.75%+188.60% 20.06B
+0.21%+3.76%+66.67%+133.69% 17.19B
Average +0.08%+5.24%+47.40%+61.00% 36.52B
Weighted average by Cap. -0.94%+4.05%+41.88%+53.00%
Logo Vitro Diagnostics, Inc.
Vitro Diagnostics, Inc., doing business as Vitro Biopharma, is engaged in the development, manufacturing and distribution of stem cell products and related tools for use in research, drug discovery and clinical trials. The Company's clinical products include clinical grade MSC-Gro for mesenchymal stem cell (MSC) expansion prior to transplantation; an equine MSC cell line with application to treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, and others; testing and therapies related to endogenous stem cell activation; diagnostic testing of stem cell activation and determination of stem cell functional status, and cell-based assays for discovery of stem cell activation agents and new drugs for the treatment of osteoporosis. The Company offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells.
Employees
-
  1. Stock Market
  2. Stocks
  3. VODG Stock